Pre-made Vepsitamab benchmark antibody ( Whole mAb, anti-MUC17;CD3E therapeutic antibody, Anti-MUC-17/MUC-3/MUC3;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-708

Pre-Made Vepsitamab biosimilar, Whole mAb, Anti-MUC17;CD3E Antibody: Anti-MUC-17/MUC-3/MUC3;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-708-1mg 1mg Inquiry
GMP-Bios-ab-708-10mg 10mg Inquiry
GMP-Bios-ab-708-100mg 100mg Inquiry
GMP-Bios-ab-708-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Vepsitamab biosimilar, Whole mAb, Anti-MUC17;CD3E Antibody: Anti-MUC-17/MUC-3/MUC3;T3E/TCRE/IMD18 therapeutic antibody
INN Name Vepsitamab
TargetMUC17;CD3E
FormatBispecific scFv-scFv-scFc
DerivationHumanized
Species ReactivityHuman
CH1 Isotypena;na
VD LCLambda;Lambda
Highest_Clin_Trial (Jan '20)Phase-I
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2021
Year Recommendedna
CompaniesAmgen
Conditions Approvedna
Conditions ActiveGE Junction Cancer;Gastric Adenocarcinoma
Conditions Discontinuedna
Development TechBiTE Technology